According to the news on June 29 from Middle East News Agency (MENA), Favipiravir, the popular drug applied for treating COVID-19 has given remarkable results in clinical tests.

AP, Fox and Deutsche Presse-Agentur have also revealed the important role of Favipiravir in the successful fight against the virus in China.

Favipiravir was first developed by Toyama Chemical Co., Ltd. In 2016, the patent of Favipiravir was particularly franchised to Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun), which collaborated with CMAM to develop Favipiravir tablets.

The finished drug was adopted quickly in the Chinese market in February 2020.

Since the outbreak of COVID-19, Favipiravir has been heavily recommended by the Chinese and Japanese governments and used in clinical tests for treating COVID-19 since February.

Now it has been included in the diagnosis and treatment guidelines of Saudi Arabia, UAE and many other countries, and has been acknowledged for indications of the disease in Russia and India.

Stanford Medicine in the US and the Italian Medicines Agency (AIFA) has established tests on the efficacy of Favipiravir on the new coronavirus as well.

The continuing global multicenter clinical trials of Favipiravir in treating COVID-19 have displayed extraordinary efficiency and safety.

Trial findings of Hisuns Favipiravir versus other drugs used in treating the virus from the Third Peoples Hospital of Shenzhen showed that those who took Favipiravir turned negative in viral nucleic acid tests in a shorter period (4 days), compared to the control group (11 days); higher improvement rate in chest imaging of 91.43% versus 62.22%, as well as a higher level of safety.

Exciting results had also been reported in the early clinical trials of Favipiravir in Russia and Bangladesh: 60% of the Russian patients (40 in total) and 48% (50 in total) of Bangladeshi patients turned negative after 4-5 days, all without obvious adverse reactions or side effects.

The good-quality Hisuns Favipiravir in ample supply has been through all channels across China.

Having a close eye on the global fight against COVID-19, Hisun has sent Favipiravir to help over 20 countries since this March.

Currently, it has built long-term partnerships with seven Middle East countries in continued care for their fight against the virus.